Commenting on today’s announcement, Professor Désiré Collen, CEO of ThromboGenics said: “We are delighted to have successfully completed our IPO and to have been able to secure the interest of high quality institutional investors. I view this positive outcome as a reflection of our strong equity story and investors’ confidence in ThromboGenics’ growth prospects. The funds raised will enable us to advance the development of our promising pipeline of products to address a broad range of conditions related to the vascular system, including back of the eye disease, stroke and peripheral vascular diseases.”
Offering highlights
· The offering was 15% oversubscribed. · Placement of 7,777,778 new shares with VVPR strips at €4.50 per share, providing ThromboGenics with gross proceeds of €35 million. Together with the existing shares, the number of outstanding shares will be 22,140,305, representing a market capitalisation of approximately €100 million immediately after the IPO. · 20% of the total offering will be allocated to retail investors in Belgium and 80% to institutional investors across Europe. · Subscriptions of retail investors will be allocated a rato 100% for subscriptions up to 2,500 shares, and a rato 85% for subscriptions above 2,501 shares. Subscriptions of institutional investors will also be reduced. · KBC Securities acted as Lead Manager to the listing. · The Lead Manager is granted an over-allotment option, exercisable as of the first listing date until 30 days thereafter, to purchase additionally 777,778 shares at the IPO price. The shares covered by the over-allotment option are existing shares that will be lent by the Selling Shareholders to the Lead Manager and have no separate VVPR strip. · The shares and VVPR strips will be listed and traded on the Eurolist by Euronext Brussels as of 7th July on an “as if-and-when-issued” basis under the symbol THR (shares) and THRS (VVPR strips). Delivery and payment of the ThromboGenics shares will be made on 11th July 2006. · The current shareholders have entered into a lock-up period which will expire in 12 months from the first listing date. During the last six months of the lock-up period (the “soft” lock-up period), the lock-up obligations will, under certain conditions, not apply to an organised sale of shares in the Issuer.
New independent director appointment
On 4 July 2006, the shareholders’ meeting of ThromboGenics NV decided to revoke its decision de dato 7 June 2006 to appoint Herman Daems as independent director, upon his own request, and, subject to the same condition precedent of establishment of the capital increase in cash in association with the IPO, to appoint Luc Philips instead as new independent director.
Luc Philips has a degree in commercial and financial sciences from the Hoger Instituut voor Bestuurs- en Handelswetenschappen (HIBH) in Brussels. In 1997, he was appointed to the board of directors and the executive committee of Kredietbank. From 1998 to 2003, he was managing director of the KBC Bank and Insurance Holding Company and KBC Bank. He was appointed managing director of Almanij in 2003. In the same year, he was also appointed director of the KBC Bank and Insurance Holding Company, KBC Bank, KBC Insurance and KBL, and became chairman of the audit committee of the first three of these companies. After the merger of KBC Bank and Insurance Holding Company and Almanij, Luc Philips remained chairman of the audit committee of KBC Group NV and KBC Bank, joined the audit committee of KBC Insurance, and became chairman of the board of directors of KBC Insurance and deputy chairman of the board of directors of KBC Bank. Furthermore, he serves on various boards of directors of companies part of KBC Group NV, of which two are active in Central Europe (K&H Bank in Hungary and Kredyt Bank in Poland), and he is a member of the board of directors of Norkom Technologies (Ireland) en of Gemma Frisius Fonds (Belgium).
For further information please contact: ThromboGenics Prof Désiré Collen, CEO Tel: (0) 16 34 61 94 Citigate Dewe Rogerson David Dible / Valerie Auffray Tel: (0) 207 638 95 71
About ThromboGenics
ThromboGenics is a company headquartered in Leuven, Belgium focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for acute stroke and peripheral arterial occlusive disease. ThromboGenics also has five other drug candidates in preclinical development with preclinical proof-of-principle demonstrated, including TB-402 (Anti-Factor VIII) and TB-403 (Anti-PlGF). The Company has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics has subsidiaries in Ireland and the U.S. More information is available at www.thrombogenics.com.
